People who suffered from myocarditis after receiving an mRNA-based COVID-19 vaccine were found to have persistently higher levels of circulating spike protein compared to those who also received an mRNA-based COVID-19 vaccine but did not develop myocarditis, according to findings from a new study.
The study, published Jan. 4 in the Journal of the American Heart Association, sought to understand better the immune profiles—also referred to as immunoprofiles—of people who suffered from myocarditis after receiving an mRNA-based vaccine.